Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy.
By Amaar H Ghazale, S. Chari, Lizhi Zhang, T. Smyrk, N. Takahashi, M. Levy, M. Topazian, J. Clain, R. Pearson, B. Petersen and 3 more. Gastroenterology, 2008
850 citations recorded by the source corpus.
Subfields: Hepatology, Rheumatology, Surgery
View Paper: https://www.semanticscholar.org/paper/717e2f485d98e8867c38fc54493485c9adf62a47
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Hepatology
Citations in the corpus
- A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details (2011, neutral): “[41].”
- EASL Clinical Practice Guidelines: management of cholestatic liver diseases. (2009, background): “plasma cells per high power field in bile duct biopsies) and shows an adequate response to a 4-week course of corticosteroid treatment to allow stent removal without relapse of obstructive cholestasis, to reach serum liver tests <2 ULN, and to present decreasing IgG4 and CA 19-9 [159].”
- Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update (2012, background): “%) developed CC.”
- IgG4-Related Disease: Recommendations for the Nomenclature of this Condition and its Individual Organ System Manifestations (2012, neutral): “Distinguishing between the primary and IgG4-related forms of sclerosing cholangitis is essential (but not always possible) because of the significant differences in treatment responses observed in these two conditions (17).”